多药耐药非发酵革兰阴性杆菌感染的新治疗方法。
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.
机构信息
Carolina Garcia-Vidal, Department of Infectious Diseases, Hospital Clinic of Barcelona, C/ Villarroel 170, 08036 Barcelona, Spain.
出版信息
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):51-53. doi: 10.37201/req/s03.12.2022. Epub 2022 Oct 24.
Abstract
Ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol belong to a novel generation of antibiotics that correspond with the β-lactam family. It is necessary to having new options in treating infections caused by Gram-negative, non-fermenting multidrug-resistant bacilli due to the significant increase in multidrug resistance in the last decades. Knowing the main characteristics of each drug is key for correct use.
摘要
头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦和头孢地尔属于β-内酰胺类抗生素的新一代药物。由于近几十年来多药耐药性的显著增加，需要有新的选择来治疗革兰氏阴性、非发酵多药耐药杆菌引起的感染。了解每种药物的主要特征是正确使用的关键。
相似文献
1
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):51-53. doi: 10.37201/req/s03.12.2022. Epub 2022 Oct 24.
2
A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
Int J Antimicrob Agents. 2024 Sep;64(3):107266. doi: 10.1016/j.ijantimicag.2024.107266. Epub 2024 Jul 5.
3
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
4
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. Epub 2021 Dec 20.
5
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
6
Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam.
Braz J Microbiol. 2024 Mar;55(1):333-341. doi: 10.1007/s42770-023-01193-x. Epub 2023 Dec 22.
7
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
Microbiol Spectr. 2023 Feb 14;11(1):e0443722. doi: 10.1128/spectrum.04437-22. Epub 2023 Jan 24.
8
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
9
[New cephalosporins].
Rev Chilena Infectol. 2018;35(5):465-475. doi: 10.4067/s0716-10182018000500465.
10
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241.
引用本文的文献
1
The genomic configurations driving antimicrobial resistance and virulence in colistin resistant Pseudomonas aeruginosa from an Egyptian Tertiary Oncology Hospital.
PLOS Glob Public Health. 2025 Aug 5;5(8):e0004976. doi: 10.1371/journal.pgph.0004976. eCollection 2025.
2
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options.
Antibiotics (Basel). 2025 Mar 16;14(3):306. doi: 10.3390/antibiotics14030306.
3
The Challenge of Bacteremia Treatment due to Non-Fermenting Gram-Negative Bacteria.
Microorganisms. 2023 Mar 30;11(4):899. doi: 10.3390/microorganisms11040899.
4
Whole-Genome Sequencing-Based Resistome Analysis of Nosocomial Multidrug-Resistant Non-Fermenting Gram-Negative Pathogens from the Balkans.
Microorganisms. 2023 Mar 3;11(3):651. doi: 10.3390/microorganisms11030651.
本文引用的文献
1
Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0199021. doi: 10.1128/AAC.01990-21. Epub 2021 Nov 22.
2
Recommendations for antibiotic selection for severe nosocomial infections.
Rev Esp Quimioter. 2021 Oct;34(5):511-524. doi: 10.37201/req/126.2021. Epub 2021 Oct 25.
3
Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
BMC Microbiol. 2021 Feb 22;21(1):60. doi: 10.1186/s12866-021-02108-2.
4
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
J Antimicrob Chemother. 2021 May 12;76(6):1379-1391. doi: 10.1093/jac/dkab015.
5
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Infect Dis. 2021 Feb;21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3. Epub 2020 Oct 12.
6
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
7
Cefiderocol: A Siderophore Cephalosporin.
Ann Pharmacother. 2020 Dec;54(12):1215-1231. doi: 10.1177/1060028020929988. Epub 2020 Jun 10.
8
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.
Kidney Int. 2020 Jun;97(6):1117-1129. doi: 10.1016/j.kint.2020.02.010. Epub 2020 Mar 9.
9
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.
Clin Microbiol Rev. 2019 Aug 28;32(4). doi: 10.1128/CMR.00031-19. Print 2019 Sep 18.
10
Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance.
Clin Infect Dis. 2020 Mar 3;70(6):1068-1074. doi: 10.1093/cid/ciz319.
Zotero 插件